Immune "Gemini" was approved by the National Medical Products Administration for the first-line treatment of malignant pleural mesothelioma

June 11, 2021, Bristol-Myers Squibb announced satisfied that Wu Yi Li You monoclonal antibody injection combined with matching wood monoclonal antibody injection by the Chinese State Drug Administration Board approved for unresectable, previously untreated non-malignant epithelioid Adult patients with pleural mesothelioma
.

This is the first indication for dual immune combination therapy approved in China, marking the world's first CTLA-4 inhibitor ipilimumab injection officially landed in China

Management Immunity

This approval is based on a clinical study called CheckMate-743, which is the first and currently the only proof that first-line dual immunotherapy compared to standard platinum-containing chemotherapy can bring survival benefits to all patients with malignant pleural mesothelioma (MPM) A randomized, phase III clinical study
.

The results of the study showed that at the shortest follow-up of 22 months, the median OS of patients in the dual immunotherapy group was 18.

This approval is based on a clinical study called CheckMate-743, which is the first and currently the only proof that first-line dual immunotherapy compared to standard platinum-containing chemotherapy can bring survival benefits to all patients with malignant pleural mesothelioma (MPM) A randomized, phase III clinical study
.

Patients were stratified randomly according to histological type.
The survival of patients with non-epithelioid and epithelioid pleural mesothelioma treated with nivolumab injection combined with ipilimumab injection was improved in non-epithelial tissues.
The advantages observed in the subgroup of type patients are greater
.
Mesothelioma is a rare and highly aggressive malignant tumor that originates in mesothelial cells.
About 3,000 cases are diagnosed in China each year, mainly pleural mesothelioma
.
Diagnosis As the first approved systemic therapy in 15 years, nivolumab injection combined with Evod has brought twice the overall survival benefit of chemotherapy for non-epithelial patients, making long-term survival of patients possible and a milestone.
The significance of this is expected to become the new standard treatment for malignant pleural mesothelioma
.

In the latest "Chinese Society of Clinical Oncology (CSCO) Immune Checkpoint Inhibitors Clinical Application Guidelines (2021 Edition)", nivolumab injection combined with ipilimumab injection is the first-line treatment of non-epithelial and epithelial Pleural mesothelioma has become the only treatment option that has received Class I (Class 1 evidence) and Class II recommendations (Class 2A evidence)
.

Nivolumab injection combined with ipilimumab injection is a unique combination of two immune checkpoint inhibitors, which target two different checkpoints (PD-1 and CTLA-4) to help destroy tumor cells Tumor immunity
nivolumab injection combined with ipilimumab injection brings significant and long-lasting overall survival benefits for patients with advanced malignant pleural mesothelioma through potential synergy, making it possible to "de-chemotherapy"
.
Wu Yilong Colorectal Cancer Leave a message here